Business
Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress
Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026
About this update from Rigel Pharmaceuticals, Inc.
[{"type":"text","content":"Oral presentation at ASCO Annual Meeting to feature final data from the Phase 3 AcceleRET-Lung clinical trial of GAVRETO® (pralsetinib) as first-line treatment in patients with RET fusion-positive NSCLCFinal analysis from the Phase 1/2 ARROW clinical trial of pralsetinib in patients with advanced or metastatic RET-altered thyroid cancer to be presented in a poster sessionReal-world data further supports the use of REZLIDHIA® (olutasidenib) in patients with R/R mIDH1 AML that have received prior venetoclaxSOUTH SAN FRANCISCO, Calif., May 21, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the final data from the Phase 3 AcceleRET-Lung clinical trial of GAVRETO® (pralsetinib) as first-line treatment of rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) will be presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting on Friday, May 29, 2026.In addition, the ASCO Annual Meeting and European Hematology Association (EHA) 2026 Congress will feature poster presentations that include additional data for pralsetinib and data for REZLIDHIA® (olutasidenib) for the treatment of relapsed or refractory (R/R) isocitrate dehydrogenase-1 (mIDH1)-mutated acute myeloid leukemia (AML). The ASCO Annual Meeting is being held in Chicago, Illinois and virtually from May 29 to June 2, 2026 and the EHA2026 Congress is being held in Stockholm, Sweden and virtually from June 11 to June 14, 2026.\"Having an oral presentation at ASCO as well as multiple additional data presentations at both upcoming medical conferences underscores the continued clinical relevance of our oncology portfolio. We're pleased that data from the AcceleRET-Lung clinical study will be presented for the first time and the real-world outcome data for olutasidenib will be presented for patients with relapsed/refractory mIDH1 AML previously treated with venetoclax, further validating its role as a treatment option for these patients,\" said Raul Rodriguez, Rigel's president and CEO. \"Together, these data reinforce our ability to deliver targeted therapies that significantly improve the lives of patients with difficult-to-treat cancers. We look forward to sharing these dat...